|
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma Clinical research trials and Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma. Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma clinical trial. Test subjects typically obtain the finest healthcare available for their Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma  Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
For Condition: recurrent adult brain tumor,adult anaplastic oligodendroglioma,adult glioblastoma multiforme,adult anaplastic astrocytoma,Mixed Gliomas
Status: No longer recruiting
Sponsor(s): North American Brain Tumor Consortium , National Cancer Institute (NCI)
Synopsis: RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining gefitinib with temozolomide in treating patients who have malignant primary glioma.
Details: OBJECTIVES: - Determine the maximum tolerated dose of gefitinib when given in combination with temozolomide in patients with malignant primary glioma. - Determine the toxic effects of this regimen in these patients. - Determine the pharmacokinetics of this regimen in these patients. OUTLINE: This is a multicenter, dose-escalation study of gefitinib. Patients are stratified according to use of concurrent enzyme-inducing anti-epileptic drugs (yes vs no). Patients receive oral gefitinib once daily on days 1-35 and oral temozolomide once daily on days 8-12 for the first course only. For the second and subsequent courses, patients receive oral gefitinib once daily on days 1-28 and oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed every 2 months for 1 year and then every 3-6 months thereafter. PROJECTED ACCRUAL: Approximately 3-42 patients will be accrued for this study within 1-14 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed malignant primary glioma - Glioblastoma multiforme - Anaplastic astrocytoma - Anaplastic oligodendroglioma - Anaplastic mixed oligoastrocytoma - Malignant astrocytoma not otherwise specified - Stable or progressive disease - Progressive disease after interstitial brachytherapy or stereotactic radiosurgery must be confirmed by positron emission tomography or thallium scan, magnetic resonance spectroscopy, or surgical biopsy - Prior treatment for no more than 3 prior relapses allowed PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 60-100% Life expectancy: - More than 8 weeks Hematopoietic: - WBC greater than 3,000/mm^3 - Absolute neutrophil count greater than 1,500/mm^3 - Platelet count greater than 120,000/mm^3 - Hemoglobin greater than 10 g/dL (transfusion allowed) Hepatic: - Bilirubin less than 1.5 times upper limit of normal (ULN) - SGOT less than 1.5 times ULN Renal: - Creatinine less than 1.5 mg/dL OR - Creatinine clearance greater than 60 mL/min Other: - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception - No active infection - No other concurrent significant medical illness that would preclude study participation - No significant gastrointestinal risk factors (e.g., active ulcerative colitis) within the past 6 months - No other malignancy within the past 3 years except non-melanoma skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 1 week since prior interferon - No concurrent filgrastim (G-CSF) during the first course of study therapy Chemotherapy: - At least 2 weeks since prior vincristine - At least 3 weeks since prior procarbazine - At least 6 weeks since prior nitrosoureas - Prior or concurrent temozolomide allowed if there is no evidence of progression while receiving therapy Endocrine therapy: - At least 1 week since prior tamoxifen - Must be on a stable dose of corticosteroids for at least 5 days Radiotherapy: - See Disease Characteristics - At least 3 weeks since prior radiotherapy Surgery: - See Disease Characteristics - At least 1 week since prior surgical resection Other: - Recovered from all prior therapy - No prior gefitinib - At least 1 week since prior non-cytotoxic agents except radiosensitizers - At least 4 weeks since prior cytotoxic therapy - At least 4 weeks since prior investigational agents - At least 3 years since prior therapy for other malignancy - Concurrent therapeutic agents allowed at stable dosage - Concurrent enzyme-inducing anti-epileptic drugs allowed if continued during study participation
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MichaelPrados, Study Chair, University of California, San Francisco
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, 02115
United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009
United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78284-6220
United States
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
United States
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, 20892-1182
United States
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15232
United States
Simmons Cancer Center - Dallas
Dallas, Texas, 75390-9154
United States
UCSF Comprehensive Cancer Center
San Francisco, California, 94143-0128
United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792
United States
Additional Information:
Study ID Numbers: CDR0000069049; NABTC-0102
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00027625
Other Mixed Gliomas Studies:
1. Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
2. Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
3. Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
4. Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
5. Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Related Studies:
Other Mixed Gliomas Clinical Trials
Other Texas Clinical Trials
Other Dallas Clinical Trials
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
|
|
|
|
|
|
|
|
